Patents by Inventor Christopher F. Bender
Christopher F. Bender has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11993574Abstract: Disclosed herein are compounds of the formula: as well as analogs thereof, wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used to modulate the activity of IL-17 and ROR?. Also provided are methods of administering compounds and composition provided herein to a patient in need thereof, for example, for the treatment or prevention of diseases or disorders associated with inflammation or for autoimmune disorders.Type: GrantFiled: June 17, 2019Date of Patent: May 28, 2024Assignee: REATA PHARMACEUTICALS, INCInventors: Xin Jiang, Melean Visnick, Christopher F. Bender, Gary Bolton, Bradley Caprathe, Chitase Lee, Brian Kornberg, Patrick O'Brien, Martha R. Hotema
-
Patent number: 11827664Abstract: Provided are biaryl amides and coumarin-based compounds with modified sugar groups for treatment of diseases associated with heat shock protein pathway. The compounds having the following formulas, wherein variables are as defined herein. Formulae (I), (II), (III), (IV), and (V), Pharmaceutical compositions of the compounds are also provided. These biaryl amides and coumarin-based derivatives with modified sugar groups are useful for treatment and prevention of diseases and disorders, including neurological disorders, such as neurodegenerative diseases and nerve damaging disorders, for example, diabetic peripheral neuropathy.Type: GrantFiled: May 14, 2019Date of Patent: November 28, 2023Assignee: REATA PHARMACEUTICALS, INCInventors: Xin Jiang, Melean Visnick, Christopher F. Bender, Gary Bolton, Bradley Caprathe, Chitase Lee
-
Publication number: 20230111914Abstract: In some aspects, the present disclosure provides compounds of the formula: (I) and (II), wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used as antioxidant inflammation modulators. In some aspects, the present disclosure provides methods wherein the compounds and composition described herein are used for the treatment of diseases and disorders associated with inflammation and cancer.Type: ApplicationFiled: December 18, 2020Publication date: April 13, 2023Inventors: Christopher F. BENDER, Ha DO, Xin JIANG, Haizhou SUN, Melean VISNICK, Ingo JANSER, Lloyd J. SIMONS, Heinrich J. SCHOSTAREZ
-
Patent number: 11406648Abstract: Disclosed herein are novel C17-heteroaryl derivatives of oleanolic acid, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds, for example, as antioxidant inflammation modulators, and compositions thereof are also provided.Type: GrantFiled: December 28, 2020Date of Patent: August 9, 2022Assignee: REATA PHARMACEUTICALS, INC.Inventors: Xin Jiang, Christopher F. Bender, Melean Visnick
-
Publication number: 20220135534Abstract: Disclosed herein are compounds of the formulas: as well as analogs thereof, wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used to inhibit ROR? and/or reduce the expression of IL-17. Also provided are methods of administering compounds and composition provided herein to a patient in need thereof, for example, for the treatment or prevention of diseases or disorders associated with inflammation or autoimmune disorders.Type: ApplicationFiled: January 18, 2022Publication date: May 5, 2022Applicant: REATA PHARMACEUTICALS, INC.Inventors: Xin JIANG, Christopher F. BENDER, Melean VISNICK, Martha R. HOTEMA, Zachary S. SHELDON, Chitase LEE, Bradley William CAPRATHE, Gary BOLTON, Brian KORNBERG
-
Patent number: 11292781Abstract: Disclosed herein are compounds of the formulas: as well as analogs thereof, wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used to inhibit ROR? and/or reduce the expression of IL-17. Also provided are methods of administering compounds and composition provided herein to a patient in need thereof, for example, for the treatment or prevention of diseases or disorders associated with inflammation or autoimmune disorders.Type: GrantFiled: December 16, 2017Date of Patent: April 5, 2022Assignee: REATA PHARMACEUTICALS, INC.Inventors: Xin Jiang, Christopher F. Bender, Melean Visnick, Martha R. Hotema, Zachary S. Sheldon, Chitase Lee, Bradley William Caprathe, Gary Bolton, Brian Kornberg
-
Publication number: 20210292281Abstract: Disclosed herein are compounds of the formula: as well as analogs thereof, wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used to modulate the activity of IL-17 and ROR?. Also provided are methods of administering compounds and composition provided herein to a patient in need thereof, for example, for the treatment or prevention of diseases or disorders associated with inflammation or for autoimmune disorders.Type: ApplicationFiled: June 17, 2019Publication date: September 23, 2021Applicant: REATA PHARMACEUTICALS, INC.Inventors: Xin JIANG, Melean VISNICK, Christopher F. BENDER, Gary BOLTON, Bradley CAPRATHE, Chitase LEE, Brian KORNBERG, Patrick O'BRIEN, Martha R. HOTEMA
-
Publication number: 20210261592Abstract: Provided are biaryl amides and coumarin-based compounds with modified sugar groups for treatment of diseases associated with heat shock protein pathway. The compounds having the following formulas, wherein variables are as defined herein. Formulae (I), (II), (III), (IV), and (V), Pharmaceutical compositions of the compounds are also provided. These biaryl amides and coumarin-based derivatives with modified sugar groups are useful for treatment and prevention of diseases and disorders, including neurological disorders, such as neurodegenerative diseases and nerve damaging disorders, for example, diabetic peripheral neuropathy.Type: ApplicationFiled: May 14, 2019Publication date: August 26, 2021Applicant: REATA PHARMACEUTICALS, INC.Inventors: Xin JIANG, Melean VISNICK, Christopher F. BENDER, Gary BOLTON, Bradley CAPRATHE, Chitase LEE
-
Patent number: 11059792Abstract: Disclosed herein are compounds of the formula: (I), wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used as antioxidant inflammation modulators. In some aspects, the present disclosure provides methods wherein the compounds and composition described herein are used for the treatment of diseases and disorders associated with inflammation and cancer.Type: GrantFiled: February 12, 2016Date of Patent: July 13, 2021Assignee: REATA PHARMACEUTICALS, INC.Inventors: Xin Jiang, Bradley William Caprathe, Chitase Lee, Gary Bolton, Christopher F. Bender, Melean Visnick
-
Publication number: 20210137947Abstract: Disclosed herein are novel C17-heteroaryl derivatives of oleanolic acid, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds, for example, as antioxidant inflammation modulators, and compositions thereof are also provided.Type: ApplicationFiled: December 28, 2020Publication date: May 13, 2021Applicant: REATA PHARMACEUTICALS, INC.Inventors: Xin JIANG, Christopher F. BENDER, Melean VISNICK
-
Publication number: 20210040142Abstract: Disclosed herein are compounds of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used as antioxidant inflammation modulators. In some aspects, the present disclosure provides methods wherein the compounds and composition described herein are used for the treatment of diseases and disorders, including those associated with inflammation and cancer.Type: ApplicationFiled: July 20, 2020Publication date: February 11, 2021Applicant: REATA PHARMACEUTICALS, INC.Inventors: Xin JIANG, Christopher F. BENDER, Ha DO, Haizhou SUN, Melean VISNICK
-
Patent number: 10898499Abstract: Disclosed herein are novel C17-heteroaryl derivatives of oleanolic acid, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds, for example, as antioxidant inflammation modulators, and compositions thereof are also provided.Type: GrantFiled: July 31, 2019Date of Patent: January 26, 2021Assignee: REATA PHARMACEUTICALS, INC.Inventors: Xin Jiang, Christopher F. Bender, Melean Visnick
-
Publication number: 20200131148Abstract: Disclosed herein are compounds of the formulas: as well as analogs thereof, wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used to inhibit ROR? and/or reduce the expression of IL-17. Also provided are methods of administering compounds and composition provided herein to a patient in need thereof, for example, for the treatment or prevention of diseases or disorders associated with inflammation or autoimmune disorders.Type: ApplicationFiled: December 16, 2017Publication date: April 30, 2020Applicant: REATA PHARMACEUTICALS, INC.Inventors: Xin JIANG, Christopher F. BENDER, Melean VISNICK, Martha R. HOTEMA, Zachary S. SHELDON, Chitase LEE, Bradley William CAPRATHE, Gary BOLTON, Brian KORNBERG
-
Publication number: 20200129530Abstract: Disclosed herein are novel C17-heteroaryl derivatives of oleanolic acid, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds, for example, as antioxidant inflammation modulators, and compositions thereof are also provided.Type: ApplicationFiled: July 31, 2019Publication date: April 30, 2020Applicant: REATA PHARMACEUTICALS, INC.Inventors: Xin JIANG, Christopher F. BENDER, Melean VISNICK
-
Patent number: 10501489Abstract: Disclosed herein are novel C17-alkanediyl and alkenediyl derivatives of oleanolic acid, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds, for example, as antioxidant inflammation modulators, and compositions thereof are also provided.Type: GrantFiled: February 15, 2017Date of Patent: December 10, 2019Assignee: REATA PHARMACEUTICALS, INC.Inventors: Christopher F. Bender, Xin Jiang, Eric Anderson, Melean Visnick
-
Patent number: 10398711Abstract: Disclosed herein are novel C17-heteroaryl derivatives of oleanolic acid, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds, for example, as antioxidant inflammation modulators, and compositions thereof are also provided.Type: GrantFiled: January 3, 2018Date of Patent: September 3, 2019Assignee: REATA PHARMACEUTICALS, INC.Inventors: Xin Jiang, Christopher F. Bender, Melean Visnick
-
Publication number: 20180235981Abstract: Disclosed herein are novel C17-heteroaryl derivatives of oleanolic acid, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds, for example, as antioxidant inflammation modulators, and compositions thereof are also provided.Type: ApplicationFiled: January 3, 2018Publication date: August 23, 2018Applicant: REATA PHARMACEUTICALS, INC.Inventors: Xin JIANG, Christopher F. BENDER, Melean VISNICK
-
Publication number: 20180127380Abstract: Disclosed herein are compounds of the formula: (I), wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used as antioxidant inflammation modulators. In some aspects, the present disclosure provides methods wherein the compounds and composition described herein are used for the treatment of diseases and disorders associated with inflammation and cancer.Type: ApplicationFiled: February 12, 2016Publication date: May 10, 2018Applicant: REATA PHARMACEUTICALS, INC.Inventors: Xin JIANG, Bradley William CAPRATHE, Chitase LEE, Gary BOLTON, Christopher F. BENDER, Melean VISNICK
-
Patent number: 9889143Abstract: Disclosed herein are novel C17-heteroaryl derivatives of oleanolic acid, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds, for example, as antioxidant inflammation modulators, and compositions thereof are also provided.Type: GrantFiled: November 11, 2016Date of Patent: February 13, 2018Assignee: REATA PHARMACEUTICALS, INC.Inventors: Xin Jiang, Christopher F. Bender, Melean Visnick
-
Publication number: 20170260227Abstract: Disclosed herein are novel C17-alkanediyl and alkenediyl derivatives of oleanolic acid, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds, for example, as antioxidant inflammation modulators, and compositions thereof are also provided.Type: ApplicationFiled: February 15, 2017Publication date: September 14, 2017Applicant: REATA PHARMACEUTICALS, INC.Inventors: Christopher F. BENDER, Xin JIANG, Eric ANDERSON, Melean VISNICK